Growth hormone

CJC-1295 with DAC

CJC 1295 with DAC

CJC-1295 with DAC is an albumin-binding growth hormone-releasing factor analogue. The reactive conjugation group is part of its identity and must not be dropped when describing the molecule.

Reviewed September 2026

Residues
30. verified: 30 residues: the substituted 29-residue GRF chain plus the added C-terminal DAC-bearing lysine. The maleimide group is not a residue.
Average mass
3,647.2 Da. verified: Reference form: CJC-1295 with DAC, unbound reference molecule: modified GRF(1–29) plus a terminal Lys bearing maleimidopropionamide; not the albumin conjugate or the without-DAC designation.; formula C165H269N47O46. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement.
pI
Not established. unverified: No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH.

Reference details

Reference details
Residues30
Average mass3,647.2 Da
pINot established
Identity
AliasesCJC 1295 with DAC
Research areaGrowth hormone

Property basis and sources

These describe the reference compound or formulation, not identification or testing of the supplied lot.

CJC-1295 with DAC, unbound reference molecule: modified GRF(1–29) plus a terminal Lys bearing maleimidopropionamide; not the albumin conjugate or the without-DAC designation. Reference only, not a sold-lot measurement.

  • Residues: 30 (verified). 30 residues: the substituted 29-residue GRF chain plus the added C-terminal DAC-bearing lysine. The maleimide group is not a residue. Residues source 1 Residues source 2 Residues source 3
  • Average mass: 3,647.2 Da (verified). Reference form: CJC-1295 with DAC, unbound reference molecule: modified GRF(1–29) plus a terminal Lys bearing maleimidopropionamide; not the albumin conjugate or the without-DAC designation.; formula C165H269N47O46. PubChem average molecular weight, not monoisotopic mass. Excludes unlisted counterions, solvent and formulation ingredients; not a sold-lot measurement. Average mass source 1
  • pI: Not established (unverified). No documented pI or validated full modification-aware ionization model was established for this exact reference form. Terminal chemistry, noncanonical residues, lipidation, cyclization or non-alpha linkages cannot be silently omitted. Not formulation pH. pI source 1

Reference scope and linked records

Reference type: Modified peptide.

This is a research-reference entry, not a product certificate, treatment recommendation or administration guide. The sources below describe their own materials and methods. Catalogue identity, lot testing and clinical evidence are separate questions.

Catalogue context: CJC 1295 with DAC. The product retains its own name and specification; this link does not certify equivalence to published study material.

Related references

Sources and their scope

  1. hGRF1-29-albumin bioconjugates: identification of CJC-1295. Source for the chemistry or study context discussed above; not an Aminos lot certificate.
  2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adults. Source for the chemistry or study context discussed above; not an Aminos lot certificate.

Source check: 26 September 2026. This is an editorial source check, not a claim of independent clinical or laboratory review.

About CJC-1295 with DAC

Identity and context

The chemistry paper describes a substituted hGRF(1–29) analogue with an added lysine derivative bearing a maleimido group. That design permits conjugation to albumin and changes persistence. A plain GRF fragment or a product labelled without DAC is therefore not equivalent.

Reference classification

Modified peptide. The linked catalogue product is CJC 1295 with DAC. This reference does not independently authenticate the material supplied.

Storage and handling

Analytical specification

Confirm that the DAC conjugation chemistry is present in the supplied structure. A specification that omits this feature cannot support interpretation using the published long-acting CJC-1295 studies.

Storage and experimental handling

Use the documented conditions for the actual chemical form and preparation. No universal storage temperature, expiry or solution shelf life is assigned here. Follow the lot documentation, safety data sheet and validated laboratory protocol; this page is not a reconstitution or administration guide.

Research evidence

Research evidence for this compound
AreaSummaryEvidence
What the source examinesThe original chemistry study evaluated albumin conjugates and hormone-release activity in experimental models. A subsequent randomized study in healthy adults measured sustained GH and IGF-I responses to CJC-1295. Those findings concern the long-acting compound used by the investigators.Source context
What cannot be inferredLong-acting study results should not be transferred to a without-DAC product or a mixture containing it. Endocrine biomarker changes are not themselves proof of a broad clinical benefit or evidence that a supplier preparation is suitable for administration.Evidence limits

References

Sources used for the data on this page, checked September 2026.

  1. hGRF1-29-albumin bioconjugates: identification of CJC-1295Primary source for the reference discussion; not lot-specific product evidence.
  2. Prolonged stimulation of GH and IGF-I secretion by CJC-1295 in healthy adultsPrimary source for the reference discussion; not lot-specific product evidence.

Reference information only. This page describes the chemistry and published research context of a laboratory compound. Nothing here is medical or dosing advice. Aminos compounds are for laboratory research use only and are not medicines.